Disease Trends

Disease Trends in Drug Development

Scroll down for details.

Sources


CTM provides three sources of information in relation to disease trends in drug development:

    • ❶ A recent comprehensive Report.
    • ❷ A weekly newsletter - CTM Weekly.
    • ❸ Ongoing disease Ranking.

Why follow disease trends?


Any person involved in industry-sponsored clinical trials should receive regular updates on the disease trends under study. The total number of trials and subjects studied has been very stable over time, implying that the industry must make strategic decisions on which disease groups should be targeted. In the past, rapid changes have taken place in the focus from one therapeutic area to another area, and from one disease to another disease. For instance, during the past decade, oncology has become the leading therapeutic area by surpassing both cardiovascular diseases and psychiatric diseases. During the recent years, Hepatitis C has become a leading disease under study, while the opposite is true for Hepatitis B, a condition once highly researched some ten years ago.

The industry closely follows changes in the drug pipeline of their competitors. When a certain disease suddenly becomes popular among many sponsors it will affect the availability of the number of clinical investigators and number of study subjects. This means the clinical development team needs to plan for such influences.

A clinical investigator involved in industry-sponsored clinical trials should continuously evaluate the size of the subject population needed for the trials in relation to the pool of patients the investigator has access to. Changes to the research interest of a disease area in clinical trials can radically change the possibility for an investigator to bid for clinical trials.

 

Download


Global Clinical Trial Trends: Therapeutic Area Winners and Losers

CTM Report - Global Clinical Trial Trends - Cover PageAuthor: Johan PE Karlberg

Published by: Clinical Trial Magnifier Limited

Published: 2014

Summary: The objective of this report is to define the overall trends for the most important diseases under clinical testing. Most of the top six therapeutic areas showed a decrease in the proportion of the number of Phase II/III trials from the first two-year period to the last two-year period. Diseases with positive trends are hepatitis C, arthritis/gout, asthma, COPD and psoriasis, constipation and kidney failure. Diseases with negative trends are breast cancer, hypertension, anemia, migraine/headache, obesity, insomnia/sleep, osteoporosis, coronary/ischemia, cardiomyopathy/failure, incontinence, thrombosis/coagulation, ADHD, renal cancer and arrhythmia/fibrillation.

Note: From February 2015, distributed by Clinical Trial Magnifier Limited only.

Clinical-Trial-Magnifier-Download

Download Report (1563 downloads)

CTM Weekly newsletter


Clinical Trial Magnifier Weekly brings you new information about essential weekly changes in the 60,000 industry-sponsored clinical studies of the US trial registry – clinicaltrials.gov.

Clinical Trial Magnifier Weekly sorts through tens of thousands of records and extracts the pivotal information you need. You’ll be able to scan through all the changes and drill down using links in the Excel file, saving you hours of effort.

Clinical Trial Magnifier Weekly breaks information down into many detailed tables in sortable spreadsheet format, perfect for analysis.

You will be able to identify new clinical trial opportunities in your area of interest and in the region that you are active in.

Read more Newsletter

Disease Ranking


The US trial registry (www.clinicaltrials.gov) includes over 150.000 clinical trials, of which one third are industry-sponsored clinical studies. The US trial registry is the most comprehensive registry. It has been estimated that 60%-70% of all industry-sponsored clinical trials are listed in the registry. We can thus use the US trial registry with confidence to visualize the globalization of industry-sponsored clinical trials.

CTM has re-coded the disease/condition for each study listed in the US Trial registry in order to obtain a more standardized disease definition. The book mentioned above includes details about the methodology of re-coding the diseases/conditions.

Please se the table below.

Disease Trends in Drug Development - searchable table


The table below provides the number of trials and anticipated number of subjects per disease.

The table include information for all interventional treatment phase II/III trials.

Updated May 18, 2018.

Please note the percentage represent the number of trials/subjects of the global count.

Table 1. Ranking between diseases: Total number of trials and subjects for phase II/III treatment trials registered in the US trials registry during the past four years. Ranking is based on the number of trials.

DISEASE RANK TRIALS (N) TRIALS (%) SUBJECTS (N) SUBJECTS (%)
ALLERGY ALLERGY 007 0136 01.87 062977 02.59
ALLERGY ASTHMA 080 0021 00.29 007759 00.32
ALLERGY CONJUNCTIVITIS 103 0017 00.23 003359 00.14
ALLERGY ECZEMA/DERMATITIS 014 0091 01.25 024394 01.00
ALLERGY RHINITIS 057 0034 00.47 012843 00.53
ANEST ANALGESIC 120 0013 00.18 002829 00.12
ANEST PAIN 064 0031 00.43 006210 00.26
ANEST PAIN ACUTE 039 0050 00.69 011478 00.47
CARDIO ARRHYT/FIBRILL 074 0025 00.34 011446 00.47
CARDIO CARDIOMYOP/FAILURE 017 0078 01.07 067603 02.78
CARDIO CHOLESTEROL/LIPIDS 012 0107 01.47 034472 01.42
CARDIO CORONARY/ISCHEMIC 056 0037 00.51 057632 02.37
CARDIO HYPERTENSION 015 0090 01.24 021361 00.88
CARDIO HYPERTENSION PULM 054 0038 00.52 004088 00.17
CARDIO INFARCT 081 0021 00.29 014633 00.60
CARDIO PERIPH VASC 050 0041 00.56 016075 00.66
CARDIO STROKE 058 0034 00.47 034182 01.40
CARDIO THROMB/COAG 053 0039 00.54 007293 00.30
DENTAL CARIES 146 0010 00.14 000745 00.03
DENTAL PERIODONTITIS 147 0010 00.14 000964 00.04
DENTAL TOOTHACHE 128 0012 00.16 003105 00.13
DERM ACNE 026 0064 00.88 036011 01.48
DERM ANGIOEDEMA 129 0012 00.16 001084 00.04
DERM HAIR LOSS 097 0018 00.25 001926 00.08
DERM HYPERHIDROSIS 130 0012 00.16 002280 00.09
DERM KERATOSIS 060 0033 00.45 009480 00.39
DERM PRURITUS 113 0014 00.19 002639 00.11
DERM PSORIASIS 005 0146 02.01 039869 01.64
DERM ROSACEA 090 0019 00.26 009656 00.40
DERM SCLERODERMA 121 0013 00.18 001695 00.07
DERM SKIN DISEASE 082 0021 00.29 002144 00.09
DERM WARTS 148 0010 00.14 001720 00.07
DERM WOUND/ULCER 098 0018 00.25 002279 00.09
DERM WRINKLES 068 0028 00.38 010968 00.45
ENDO DIABETES 001 0279 03.83 139645 05.74
ENDO DIABETES FOOT 114 0014 00.19 003353 00.14
ENDO GROWTH HORMONE 077 0022 00.30 002186 00.09
ENDO MALE HYPOGONADISM 099 0018 00.25 002247 00.09
ENDO METAB/NUTR 069 0026 00.36 005268 00.22
ENDO OBESITY 075 0025 00.34 006134 00.25
ENDO SJOGREN 104 0016 00.22 001281 00.05
GI BILIARY DISEASE 100 0018 00.25 001440 00.06
GI CONSTIPATION 047 0042 00.58 011337 00.47
GI CROHN 037 0051 00.70 023608 00.97
GI ESOPHAGITIS/REFLUX 062 0032 00.44 008190 00.34
GI GASTRIC ULCER/BLEEDING 091 0019 00.26 005677 00.23
GI LIVER CIRRHOSIS 078 0022 00.30 002848 00.12
GI LIVER FATTY 034 0053 00.73 014726 00.61
GI SCOPY 106 0015 00.21 003445 00.14
GI SMALL BOWEL 139 0011 00.15 000417 00.02
GI ULCERATIVE COLITIS 027 0064 00.88 020273 00.83
HEALTHY/PHARM 021 0069 00.95 041521 01.71
HEM ANEMIA 020 0071 00.98 030551 01.26
HEM ANEMIA IRON 122 0013 00.18 005972 00.25
HEM ANEMIA SICKLE CELL 101 0018 00.25 002020 00.08
HEM HAEMOPHILIA A/B 055 0038 00.52 002543 00.10
HEM HEMOGLOBINURIA 107 0015 00.21 000680 00.03
HEM THALASSEMIA 149 0010 00.14 000911 00.04
IMMUNE GRAFT VS. HOST 084 0020 00.27 003073 00.13
IMMUNE IMMUNODEFICIENCY 150 0010 00.14 000560 00.02
INFECT BACTERIAL 131 0012 00.16 002225 00.09
INFECT CANDIDIA 115 0014 00.19 002179 00.09
INFECT CNS: MENINGITIS 132 0012 00.16 012074 00.50
INFECT CNS: MENINGOCOCCAL 116 0014 00.19 006792 00.28
INFECT DENGUE 117 0014 00.19 008841 00.36
INFECT DERM: HERPES SIMPLEX 140 0011 00.15 007265 00.30
INFECT DERM: SKIN/SOFT TISSUE 092 0019 00.26 005297 00.22
INFECT DERM: TOENAILS 141 0011 00.15 001998 00.08
INFECT ENT: OTITIS 142 0011 00.15 003016 00.12
INFECT GI: CLOSTRIDIUM 108 0015 00.21 019396 00.80
INFECT GI: ENTERITIS 076 0023 00.32 004844 00.20
INFECT GI: HEPATITIS B 045 0043 00.59 010758 00.44
INFECT GI: HEPATITIS C 006 0138 01.90 025050 01.03
INFECT HEM: MALARIA 123 0013 00.18 007852 00.32
INFECT HERPES ZOSTER 151 0010 00.14 026465 01.09
INFECT HIV/AIDS 016 0079 01.09 035777 01.47
INFECT OG: VAGINA 102 0018 00.25 005931 00.24
INFECT RESP: INFLUENZA/FLU 011 0108 01.48 093137 03.83
INFECT RESP: PNEUMOCOCCAL 133 0012 00.16 007183 00.30
INFECT RESP: PNEUMONIA 085 0020 00.27 013564 00.56
INFECT RESP: SYNCYTIAL 061 0033 00.45 031803 01.31
INFECT RESP: TBC 109 0015 00.21 006050 00.25
INFECT UROLOGY: URINARY 093 0019 00.26 007613 00.31
INFECT VIRUS 134 0012 00.16 018192 00.75
NEUR ALS 079 0022 00.30 004209 00.17
NEUR ALZHEIMER/DEMENT 013 0098 01.35 040621 01.67
NEUR AMYLOIDOSIS 143 0011 00.15 001632 00.07
NEUR EPILEPSY/SEIZURE 022 0068 00.93 009176 00.38
NEUR FIBROMYALGIA 135 0012 00.16 007589 00.31
NEUR MIGRAINE/H-ACHE 028 0064 00.88 043033 01.77
NEUR MULTIPLE SCLEROSIS 030 0059 00.81 019782 00.81
NEUR MUSCULAR DYSTROPHY 066 0030 00.41 002367 00.10
NEUR MYASTHENIA GRAVIS 152 0010 00.14 000561 00.02
NEUR NEURALGIA 144 0011 00.15 002057 00.08
NEUR NEUROPATHY 083 0021 00.29 003477 00.14
NEUR PARKINSON 024 0066 00.91 011419 00.47
OG CONTRACEPTION 094 0019 00.26 013925 00.57
OG ENDOMETRIOSIS 110 0015 00.21 005336 00.22
OG INFERTILITY 086 0020 00.27 006796 00.28
OG MENOPAUSE POST 145 0011 00.15 001825 00.08
ONC BREAST 004 0162 02.23 052059 02.14
ONC CHEMOTHER EFFECTS 124 0013 00.18 002478 00.10
ONC CNS: GLIOMA 059 0034 00.47 004878 00.20
ONC DERM: MELANOMA 043 0044 00.60 014287 00.59
ONC ENDO: NEUROENDO 118 0014 00.19 001461 00.06
ONC ENT: NPC 038 0051 00.70 012253 00.50
ONC GI: BILIARY 087 0020 00.27 002560 00.11
ONC GI: COLORECTAL 023 0067 00.92 019404 00.80
ONC GI: ESOPHAGEAL/GASTRIC 031 0059 00.81 020961 00.86
ONC GI: LIVER 035 0053 00.73 010621 00.44
ONC GI: PANCREAS 051 0041 00.56 007216 00.30
ONC HEM: LEUKEMIA 010 0111 01.53 020295 00.83
ONC HEM: LYMPHOMA 009 0123 01.69 017227 00.71
ONC HEM: MYELODYSPLASTIC 070 0026 00.36 003237 00.13
ONC HEM: MYELOMA 025 0065 00.89 013399 00.55
ONC OG: CERVIX 095 0019 00.26 004680 00.19
ONC OG: OVARY 040 0048 00.66 012943 00.53
ONC OG: UTERUS 071 0026 00.36 007423 00.31
ONC ORTH: SARCOMA 125 0013 00.18 001480 00.06
ONC RESP: LUNG 003 0234 03.22 075295 03.09
ONC SOLID TUMOR/CANCER 029 0064 00.88 016481 00.68
ONC UROLOGY: BLADDER 042 0047 00.65 017845 00.73
ONC UROLOGY: KIDNEY 065 0031 00.43 011615 00.48
ONC UROLOGY: PROSTATE 018 0077 01.06 025817 01.06
OPHTHAL DIABETIC 067 0029 00.40 005700 00.23
OPHTHAL DRY EYE 046 0043 00.59 011185 00.46
OPHTHAL EYE DISEASE 126 0013 00.18 002377 00.10
OPHTHAL GLAUCOMA 044 0044 00.60 013471 00.55
OPHTHAL MACULAR DEGENERATION 052 0041 00.56 012454 00.51
OPHTHAL UVEITIS 119 0014 00.19 001165 00.05
ORTH BACK PAIN 072 0026 00.36 009162 00.38
ORTH JOINT DISEASE 111 0015 00.21 001624 00.07
ORTH MUSCULAR DISEASE 041 0048 00.66 005044 00.21
ORTH TENDO DISEASE 153 0010 00.14 001530 00.06
PSYCH ABUSE OPIOD/HEROIN 136 0012 00.16 003358 00.14
PSYCH ADHD 048 0042 00.58 007306 00.30
PSYCH BIPOLAR 112 0015 00.21 004283 00.18
PSYCH DEPRESSION 019 0076 01.04 024786 01.02
PSYCH INSOMNIA/SLEEP 073 0026 00.36 005420 00.22
PSYCH SCHIZOPHRENIA 032 0056 00.77 018441 00.76
PSYCH STRESS/PTSD 137 0012 00.16 002238 00.09
RESP COPD 008 0135 01.85 084035 03.45
RESP CYSTIC FIBROSIS 036 0053 00.73 006705 00.28
RESP DISEASE 138 0012 00.16 002581 00.11
RESP PULMONARY FIBROSIS 096 0019 00.26 001635 00.07
RESP RDS 154 0010 00.14 001611 00.07
RHEUM ARTHRITIS/GOUT 002 0276 03.79 106961 04.40
RHEUM LUPUS ERYTHEM. 049 0042 00.58 008365 00.34
RHEUM SPONDYLITIS 063 0032 00.44 009215 00.38
SURG COMPLICATION 105 0016 00.22 003413 00.14
UROLOGY INCONTINENCE 088 0020 00.27 005532 00.23
UROLOGY KIDNEY DISEASE 127 0013 00.18 000983 00.04
UROLOGY KIDNEY FAILURE 033 0055 00.76 013774 00.57
UROLOGY KIDNEY NEPHRITIS 089 0020 00.27 002407 00.10
UROLOGY PROSTATE HYPERPLASIA 155 0010 00.14 002432 00.10

Clinical-Trial-Magnifier-Disease-Trends-Ice

“The physician should not treat the disease but the patient who is suffering from it.”
Maimonides

If you have additional advices, questions, or comments on the contents of this page, please send us a message: Contact